Overview FTIH of ECC4703 in Healthy Volunteers Status: Recruiting Trial end date: 2023-07-05 Target enrollment: Participant gender: Summary This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL Phase: Early Phase 1 Details Lead Sponsor: Eccogene